Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis C

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 17 articles:
HTML format



Single Articles


    December 2023
  1. UOJIMA H, Nakabayashi K, Yamasaki K, Sugiyama M, et al
    New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
    J Gastroenterol. 2023;58:1252-1260.
    PubMed     Abstract available


    October 2023
  2. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    PubMed     Abstract available


    March 2023
  3. SHIMAKAMI T, Setoyama H, Oza N, Itakura J, et al
    Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan.
    J Gastroenterol. 2023;58:257-267.
    PubMed     Abstract available


    February 2023
  4. MIZUOCHI T, Iwama I, Inui A, Ito Y, et al
    Real-world efficacy and safety of glecaprevir/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study.
    J Gastroenterol. 2023 Feb 15. doi: 10.1007/s00535-023-01968.
    PubMed     Abstract available


  5. NAKAGAWA M, Asahina Y, Kakinuma S, Okamoto R, et al
    Correction: Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
    J Gastroenterol. 2023 Feb 9. doi: 10.1007/s00535-023-01961.
    PubMed    


  6. KOTANI K, Enomoto M, Uchida-Kobayashi S, Tamori A, et al
    Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
    J Gastroenterol. 2023 Feb 2. doi: 10.1007/s00535-023-01963.
    PubMed     Abstract available


    December 2022
  7. NAKAGAWA M, Asahina Y, Kakinuma S, Okamoto R, et al
    Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
    J Gastroenterol. 2022 Dec 30. doi: 10.1007/s00535-022-01940.
    PubMed     Abstract available


    July 2022
  8. GENDA T, Ichida T, Tanaka E, Mochida S, et al
    Allograft liver failure awaiting liver transplantation in Japan.
    J Gastroenterol. 2022;57:495-504.
    PubMed     Abstract available


    January 2022
  9. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
    J Gastroenterol. 2022 Jan 20. pii: 10.1007/s00535-021-01845.
    PubMed     Abstract available


  10. SEKO Y, Moriguchi M, Takahashi A, Yamaguchi K, et al
    Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
    J Gastroenterol. 2022 Jan 15. pii: 10.1007/s00535-021-01837.
    PubMed     Abstract available


    August 2021
  11. CHEN C, Yang RX, Xu HG
    STING and liver disease.
    J Gastroenterol. 2021;56:704-712.
    PubMed     Abstract available


    May 2021
  12. ITAKURA J, Kurosaki M, Setoyama H, Simakami T, et al
    Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.
    J Gastroenterol. 2021;56:470-478.
    PubMed     Abstract available


    December 2020
  13. OCHI H, Hiraoka A, Hirooka M, Koizumi Y, et al
    Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    J Gastroenterol. 2020 Dec 5. pii: 10.1007/s00535-020-01747.
    PubMed     Abstract available


    November 2020
  14. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available


    October 2020
  15. MIKI D, Akita T, Kurisu A, Kawaoka T, et al
    PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication.
    J Gastroenterol. 2020 Oct 15. pii: 10.1007/s00535-020-01731.
    PubMed     Abstract available


  16. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available


    November 2019
  17. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.
    J Gastroenterol. 2019 Nov 25. pii: 10.1007/s00535-019-01645.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.